HUP1100535A2 - Pharmaceutical composition for enhancement of stem cell treatment - Google Patents
Pharmaceutical composition for enhancement of stem cell treatmentInfo
- Publication number
- HUP1100535A2 HUP1100535A2 HU1100535A HUP1100535A HUP1100535A2 HU P1100535 A2 HUP1100535 A2 HU P1100535A2 HU 1100535 A HU1100535 A HU 1100535A HU P1100535 A HUP1100535 A HU P1100535A HU P1100535 A2 HUP1100535 A2 HU P1100535A2
- Authority
- HU
- Hungary
- Prior art keywords
- enhancement
- pharmaceutical composition
- stem cell
- cell treatment
- treatment
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000002660 stem cell treatment Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/07—Heat shock proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/72—Transferases [EC 2.]
- C12N2501/727—Kinases (EC 2.7.)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Developmental Biology & Embryology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU1100535A HUP1100535A2 (en) | 2011-09-26 | 2011-09-26 | Pharmaceutical composition for enhancement of stem cell treatment |
| PCT/HU2012/000098 WO2013045963A1 (en) | 2011-09-26 | 2012-09-25 | A pharmaceutical composition for the treatment of stem cells |
| EP12805749.4A EP2760449A1 (en) | 2011-09-26 | 2012-09-25 | A pharmaceutical composition for the treatment of stem cells |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU1100535A HUP1100535A2 (en) | 2011-09-26 | 2011-09-26 | Pharmaceutical composition for enhancement of stem cell treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUP1100535A2 true HUP1100535A2 (en) | 2013-04-29 |
Family
ID=89990452
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU1100535A HUP1100535A2 (en) | 2011-09-26 | 2011-09-26 | Pharmaceutical composition for enhancement of stem cell treatment |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP2760449A1 (en) |
| HU (1) | HUP1100535A2 (en) |
| WO (1) | WO2013045963A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP1800298A1 (en) | 2018-08-30 | 2020-05-28 | N Gene Res Laboratories Inc | Combination of beta blocker and hydroximic acid derivative with reduced side effects |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU207988B (en) | 1988-10-20 | 1993-07-28 | Biorex Kutato Fejlesztoe Kft | Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components |
| HU222994B1 (en) | 1995-11-02 | 2004-01-28 | BIOREX Kutató és Fejlesztő Rt. | Hydroxylamine derivatives and use thereof in the preparation of a pharmaceutical compositions for enhancing of molecular chaperon production of cells |
| UA64716C2 (en) * | 1996-08-09 | 2004-03-15 | Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells | |
| HUP9900475D0 (en) | 1999-02-26 | 1999-04-28 | Biorex Kutato Fejlesztoe Kft | O-(3-piperidino-2-hydroxy-1-propyl)-hiyroximic acid-halogenid derivative, it's use for treating insulin resistance, and pharmaceutical compositions containing them as active component |
| HUP0001583A2 (en) | 2000-04-18 | 2002-11-28 | BIOREX Kutató és Fejlesztő Rt. | A pyridine-1-oxide derivative and process for its conversion to medicinal compounds |
| US8540985B2 (en) * | 2008-06-26 | 2013-09-24 | Orphazyme Aps | Use of Hsp70 as a regulator of enzymatic activity |
| US20110027771A1 (en) * | 2009-07-31 | 2011-02-03 | Artemis Health, Inc. | Methods and compositions for cell stabilization |
-
2011
- 2011-09-26 HU HU1100535A patent/HUP1100535A2/en not_active IP Right Cessation
-
2012
- 2012-09-25 WO PCT/HU2012/000098 patent/WO2013045963A1/en not_active Ceased
- 2012-09-25 EP EP12805749.4A patent/EP2760449A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013045963A1 (en) | 2013-04-04 |
| EP2760449A1 (en) | 2014-08-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2771030A4 (en) | Compositions and methods for treatment of proteinopathies | |
| PT2714059T (en) | Treatment of pain using placental stem cells | |
| PL2740796T3 (en) | Pharmaceutical composition for treatment and/or prophylaxis of cancer | |
| PT2740794T (en) | Pharmaceutical composition for treatment and/or prophylaxis of cancer | |
| EP2675458A4 (en) | Compounds and methods for treatment of hypertension | |
| EP2773754A4 (en) | Method of treatment | |
| GB201106960D0 (en) | Treatment of waste | |
| IL233111A0 (en) | Treatment of inflammation | |
| SI2691083T1 (en) | Pharmaceutical composition of sitagliptin | |
| GB201202773D0 (en) | Compositions for treatment of skin disorders | |
| SG10201605205VA (en) | Treatment of rhinitis | |
| HUE038787T2 (en) | Tripeptide compositions and their use for treatment of diabetes | |
| ZA201304743B (en) | Method for enhancing engraftment of haematopoetics stem cells | |
| EP2704702A4 (en) | Composition and method for treatment of diabetes | |
| IL234606A0 (en) | Novel methods and composition for treatment of disease | |
| EP2670243A4 (en) | Compositions and methods for treatment of glaucoma | |
| IL232065A (en) | Pharmaceutical composition for treatment of adrenal insufficiency | |
| IL231143A0 (en) | Treatment of rhinitis | |
| PH12014501052A1 (en) | Methods and compositions for the treatment of diabetes and related symptoms | |
| IL222072A (en) | Composition for treatment of essential thrombocythemia | |
| HUP1100535A2 (en) | Pharmaceutical composition for enhancement of stem cell treatment | |
| ZA201400956B (en) | Treatment of sulphidic materials | |
| ZA201409502B (en) | Composition for treatment of warts | |
| EP2785380A4 (en) | Treatment of b cell lymphomas | |
| EP2791324A4 (en) | Method of treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RH9A | Decision on the lapse of patent protection withdrawn | ||
| FA9A | Lapse of provisional patent protection due to relinquishment or protection considered relinquished | ||
| GB9A | Succession in title |
Owner name: BRACELIA INVESTMENTS LIMITED, CY Free format text: FORMER OWNER(S): DR. HAZAY BALAZS, HU |